Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment (vol 4, 24, 2018)

被引：0
|
作者：
不详
机构：
来源：
CELL DEATH DISCOVERY | 2019年 / 5卷
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
    Horiike, A.
    Kudo, K.
    Miyauchi, E.
    Ohyanagi, F.
    Kasahara, K.
    Horai, T.
    Nishio, M.
    BRITISH JOURNAL OF CANCER, 2011, 105 (08) : 1131 - 1136
  • [22] Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
    A Horiike
    K Kudo
    E Miyauchi
    F Ohyanagi
    K Kasahara
    T Horai
    M Nishio
    British Journal of Cancer, 2011, 105 : 1131 - 1136
  • [23] Gefitinib for the treatment of non-small-cell lung cancer
    Campbell, Lynn
    Blackhall, Fiona
    Thatcher, Nicholas
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (08) : 1343 - 1357
  • [24] Modulation of host glutamine anabolism of small cell lung cancer to chemotherapy
    Kodama, Manabu
    Toyokawa, Gouji
    Sugahara, Osamu
    Sugiyama, Shigeaki
    Haratake, Naoki
    Yamada, Yuichi
    Wada, Reona
    Takamori, Shinkichi
    Shimokawa, Mototsugu
    Takenaka, Tomoyoshi
    Tagawa, Tetsuzo
    Kittaka, Hiroki
    Tsuruda, Takeshi
    Tanaka, Kentaro
    Komatsu, Yushiro
    Nakata, Keisuke
    Imado, Yuri
    Yamazaki, Koji
    Okamoto, Isamu
    Oda, Yoshinao
    Takahashi, Masatomo
    Izumi, Yoshihiro
    Bamba, Takeshi
    Shimizu, Hideyuki
    Yoshizumi, Tomoharu
    Nakayama, Keiichi I.
    CELL REPORTS, 2023, 42 (08):
  • [25] Gefitinib for the treatment of non-small-cell lung cancer
    Hida, Toyoaki
    Ogawa, Shizu
    Park, Jang Chul
    Park, Ji Young
    Shimizu, Junichi
    Horio, Yoshitsugu
    Yoshida, Kimihide
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (01) : 17 - 35
  • [26] Gefitinib for non-small-cell lung cancer treatment
    D'Incecco, Armida
    Cappuzzo, Federico
    EXPERT OPINION ON DRUG SAFETY, 2011, 10 (06) : 987 - 996
  • [27] Overview of Gefitinib in Non-small Cell Lung Cancer: An Asian Perspective
    Jiang, Haiyi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (03) : 137 - 150
  • [28] Analysis of the response and toxicity to gefitinib of non-small cell lung cancer
    Konishi, J
    Yamazaki, K
    Kinoshita, I
    Isobe, H
    Ogura, S
    Sekine, S
    Ishida, T
    Takashima, R
    Nakadate, M
    Nishikawa, S
    Hattori, T
    Asahina, H
    Imura, M
    Kikuchi, E
    Kikuchi, J
    Shinagawa, N
    Yokouchi, H
    Munakata, M
    Dosaka-Akita, H
    Nishimura, M
    ANTICANCER RESEARCH, 2005, 25 (1B) : 435 - 441
  • [29] Predictors of the response to gefitinib in refractory non-small cell lung cancer
    Kim, KS
    Jeong, JY
    Kim, YC
    Na, KJ
    Kim, YH
    Ahn, SJ
    Baek, SM
    Park, CS
    Park, CM
    Kim, YI
    Lim, SC
    Park, KO
    CLINICAL CANCER RESEARCH, 2005, 11 (06) : 2244 - 2251
  • [30] Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
    Shimomura, Iwao
    Tada, Yuji
    Miura, Gen
    Suzuki, Toshio
    Matsumura, Takuma
    Tsushima, Kenji
    Terada, Jiro
    Kurimoto, Ryota
    Sakaida, Emiko
    Sekine, Ikuo
    Takiguchi, Yuichi
    Yamamoto, Shuichi
    Tatsumi, Koichiro
    CASE REPORTS IN OPHTHALMOLOGICAL MEDICINE, 2013, 2013
12345